Compositions and methods for treating cancer

A method of inhibiting MTHFD2 expression in a subject in need thereof comprising:

• administering to the subject a dsRNA agent comprising a sense strand and an antisense strand forming a double stranded region, wherein said antisense strand comprises at least 15 contiguous nucleotides and excluding any overhang is at least 80% identical to the nucleotide sequence of the complement of nucleotides 1 to 1100 of SEQ ID NO:64.

An iRNA agent for inhibiting expression of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), wherein said iRNA agent comprises an antisense strand comprising at least 15 contiguous nucleotides and excluding any overhang shares at least 80% identity to a sequence selected from the group consisting of SEQ ID NOs:

• 126 to 140.

A method for treating prostate cancer, comprising administering to a subject in need thereof one or more oligonucleotides, or a salt thereof, or a pharmaceutical agent that induces the production of the one or more oligonucleotides, wherein the one or more oligonucleotides is at least 80% identical to any one of SEQ ID NOs:

• 1 to 63 or the complement thereof, wherein said oligonucleotides hybridize to the MTHFD2 of SEQ ID NO:64 or an mRNA encoded thereof.

Oligonucleotide composition comprising one or more nucleotides, or salts thereof, or a pharmaceutical agent that induces the production of the one or more oligonucleotide, wherein the one or more oligonucleotides is at least 80% identical to any one of SEQ ID NOs:

• 1 to 63 or the complement thereof, wherein said oligonucleotides hybridize to the MTHFD2 of SEQ ID NO:64 or an mRNA encoded thereof.

An expression vector encoding an siRNA comprising a nucleic acid that expresses an RNA selected from the group consisting of SEQ ID NOs:

• 1-63 linked to a nucleic acid encoding the complement of an RNA selected from the group consisting of SEQ ID NOs:
• 1-63.